Departments: Klinik für Urologie und Urologische Onkologie

Centers: Medizinische Hochschule Hannover: Klinik für Urologie und Urologische Onkologie

Discipline

Urologie

Leitung

Prof. Dr. M. Kuczyk Germany

Studies

ID	Name	Disease	Status
OGX-011-11	Docetaxel/prednisone vs. docetaxel/prednisone + custirsen for HRPC (SYNERGY)	prostate cancer	active
C21004	Orteronel/prednisone vs. placebo/prednisone for metastatic HRPC	prostate cancer	active
C21005	Orteronel/Prednisone vs. Plecebo/Prednisone after therapy failure with docetaxel	prostate cancer	active
113387	Pazopanib for locally advanced RCC following nephrectomy (PROTECT)	renal cell carcinoma	active
OGX-427-02	Chemotherapy + OGX-427 or placebo in patients with bladder cancer	urothelial cancer	active
CRAD001LDE17T	Paclitaxel + RAD001 in urothelial carcinoma	urothelial cancer	closed
BC1-06	HRPCa with skeletal metastases (Algeta)	prostate cancer	closed
512		prostate cancer	closed
A0221045		hyperactive bladder	closed
RCC SWITCH	Sorafenib vs. sunitinib -> sunitinib vs. sorafenib	renal cell carcinoma	closed
12932	Taldalafil in patients with BPH	Prostatahyperplasie (BPH)	closed
13086	Tadalafil after radical prostatectomy (REACTT)	Erektile Dysfunktion	closed
9785-CL-0321	MDV3100 for hormone-naïve prostate cancer	prostate cancer	closed
MDV3100-03	MDV3100 for prostate cancer after failure of androgendeprivation therapy (PREVAIL)	prostate cancer	closed
A0221095	Fesoterodine 8 mg vs. 4 mg for overactive bladder	hyperactive bladder	closed

previous 1 2 next